Respiratory Syncytial Virus (RSV) Fluorescent Reporter Strain
Application
Modified RSV incorporating a red fluorescent reporter protein for vaccine, drug and biologic research & development.
Key Benefits
- Provides new and needed screening tool for RSV research.
- Fluorescent protein included has better in vivo imaging capabilities than other more commonly used fluorescent proteins.
Market Summary
RSV is a highly contagious and ubiquitous virus that causes respiratory tract infections in individuals of all ages, particularly young children and the elderly. Currently, no effective vaccine against RSV exists and treatment is limited to a non-vaccine prophylactic medication and supportive care.
Technical Summary
Dr. Moore's lab at Emory University has created a recombinant RSV strain that co-expresses a red fluorescent protein known as Katushka2. This viral strain is derived from Dr. Moore's BAC-RSV vector that carries the complete antigenomic sequence of RSV (see related Emory technology 11064). The Katushka protein, discovered in a sea anemone, is the brightest known fluorescent protein, making it ideal for penetrating tissues. This modified RSV strain could provide a means to establish flow cytometry and microscopy assays to indicate infection, which is useful for screening vaccine, drug and antibody candidates that neutralize the virus.
Developmental Stage
The Katushka2-tagged RSV strain has been successfully engineered and is available to ship.
Patent Information
| App Type |
Country |
Serial No. |
Patent No. |
File Date |
Issued Date |
Patent Status |
|
|
